Ann: Trading Halt, page-83

Hey @thevinnys, great post (as always).
One note in the grid elicited the following thought: if the patent is related to Psilocybin, there is a chance that it might focus on the accompanying therapy rather than the molecule. In which case there would not be the requirement that the molecular make-up be novel?

I'm really hoping the patent part of the announcement will be related to OSA secondary endpoints: much stronger signal since based on a 2b trial, and of course, also a welcome indication that the trial is already being considered to have a measure of success in terms of establishing commercial viability for the formulation. A GAD patent at this stage would be far more speculative IMO.

Looking forward to knowing more on Thursday!